Ambrx is now officially part of Johnson & Johnson Innovative Medicine With our world-class team and novel ADC product candidates, we have exciting opportunities ahead to advance and deliver novel targeted therapies for patients with cancer. Read here: https://lnkd.in/exgCCsa7
Ambrx
Biotechnology Research
San Diego, CA 9,321 followers
Pioneer and Leader in Next Generation Antibody Drug Conjugates Using Engineered Precision Biologics
About us
Ambrx (Nasdaq: AMAM) is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications. Specifically, ARX517, its proprietary antibody-drug conjugates (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. Ambrx spun out of The Scripps Research Institute in 2003 and has several other product candidates involving ADCs and other aspects of Ambrx’s protein engineering technology.
- Website
-
http://www.ambrx.com/
External link for Ambrx
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, CA
- Type
- Public Company
- Founded
- 2003
Locations
-
Primary
Get directions
10975 N Torrey Pines Rd
San Diego, CA 92037, US
Employees at Ambrx
Updates
-
Today we entered into a definitive agreement to be acquired by Johnson & Johnson. We are excited to join a global organization and accelerate our promising pipeline of next-gen ADCs for patients in need of targeted treatment options. Click here for more information and cautionary statements: https://bit.ly/3NVXqKl
Ambrx Announces Sale to Johnson & Johnson
globenewswire.com